VTV Therapeutics Inc. Class AVTVT
13F holders, Q1 2026 (March 31)35holders +8
9new positions
3sold out
1famous investor
$39.66avg. 13F price*
At the end of Q1 2026, 35 institutions reported holding VTV Therapeutics Inc. Class A (VTVT) in their 13F filings, up 8 from Q4 2025. 9 opened new positions and 3 sold out. The largest holders were Samsara Biocapital, LLC ($11.8M), FMR LLC ($10.3M) and Millennium Management ($8.2M). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- VTV Therapeutics Inc. Class A
- CUSIP
- 918385204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $9.7M |
| Exits | 3 | $61K |
All 13F filers, Q4 2025 → Q1 2026: 264,403 shares bought and 103,672 shares sold, net +160,731 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Samsara Biocapital, LLC | 1.15% | No change | 298,496 | $11.8M |
| FMR LLC | 0.00% | Reduce -3.1% | 260,391 | $10.3M |
| Millennium Management | 0.01% | New | 206,288 | $8.2M |
| Siren, L.L.C. | 0.18% | No change | 163,000 | $6.5M |
| Baker Bros. Advisors LP | 0.03% | No change | 148,314 | $5.9M |
| Trails Edge Capital Partners, LP | 1.30% | Reduce -39.6% | 139,578 | $5.5M |
| Vanguard Capital Management LLC | 0.00% | — | 108,922 | $4.3M |
| Geode Capital Management, LLC | 0.00% | Add +16.6% | 32,886 | $1.3M |
| Northern Trust Corp. | 0.00% | Add +12.5% | 18,052 | $716K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 16,126 | $640K |
| 683 Capital Management, LLC | 0.06% | Reduce -12.4% | 16,000 | $635K |
| Marshall Wace, LLP | 0.00% | New | 13,389 | $531K |
| Goldman Sachs Group Inc. | 0.00% | Add +141.4% | 13,350 | $529K |
| BlackRock, Inc. | 0.00% | Add +18.8% | 12,602 | $500K |
| State Street Corp. | 0.00% | New | 10,666 | $423K |
| Brevan Howard Capital Management LP | 0.00% | New | 7,531 | $299K |
| Pathstone Holdings, LLC | 0.00% | No change | 6,073 | $241K |
| UBS Group AG | 0.00% | Add +237.9% | 5,636 | $224K |
| Qube Research & Technologies Ltd | 0.00% | New | 5,618 | $223K |
| Vanguard Global Advisers, LLC | 0.00% | — | 1,275 | $51K |
| Morgan Stanley | 0.00% | Add +18.2% | 1,155 | $46K |
| Osaic Holdings, Inc. | 0.00% | Reduce -0.1% | 1,119 | $44K |
| Farther Finance Advisors, LLC | 0.00% | Add +1.4% | 283 | $11K |
| Strengthening Families & Communities, LLC | 0.00% | New | 173 | $7K |
| Bessemer Group Inc. | 0.00% | No change | 112 | $4K |
| Royal Bank of Canada | 0.00% | New | 43 | $2K |
| Activest Wealth Management | 0.00% | No change | 50 | $2K |
| CoreCap Advisors, LLC | 0.00% | No change | 45 | $2K |
| Parallel Advisors, LLC | 0.00% | No change | 38 | $2K |
| Barclays PLC | 0.00% | New | 36 | $1K |
| Sunbelt Securities, Inc. | 0.00% | No change | 15 | $595 |
| BNP Paribas Financial Markets | 0.00% | No change | 9 | $357 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 2 | $79 |
| SBI Securities Co., Ltd. | 0.00% | No change | 2 | $79 |
| Strategic Wealth Partners, Ltd. | 0.00% | No change | 1 | $40 |
"% of holder's portfolio" is VTVT's weight in each manager's 13F, not the share of VTV Therapeutics Inc. Class A the manager owns.